Published in Mol Pharmacol on October 01, 2000
Segmental duplications and copy-number variation in the human genome. Am J Hum Genet (2005) 13.33
Completing the map of human genetic variation. Nature (2007) 4.38
Co-morbidity of smoking in patients with psychiatric and substance use disorders. Am J Addict (2005) 3.89
Tobacco addiction. Lancet (2008) 3.65
Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. Lancet Respir Med (2015) 2.12
Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymes. J Neurogenet (2009) 2.07
A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13. Hum Mol Genet (2011) 1.98
Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers. Clin Pharmacol Ther (2009) 1.83
Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Naunyn Schmiedebergs Arch Pharmacol (2003) 1.50
Genetically decreased CYP2A6 and the risk of tobacco dependence: a prospective study of novice smokers. Tob Control (2004) 1.47
Genetic and environmental influences on the ratio of 3'hydroxycotinine to cotinine in plasma and urine. Pharmacogenet Genomics (2009) 1.28
Candidate gene case-control association studies: advantages and potential pitfalls. Br J Clin Pharmacol (2001) 1.24
Rapid nicotine clearance is associated with greater reward and heart rate increases from intravenous nicotine. Neuropsychopharmacology (2012) 1.21
Nicotine self-administration in mice is associated with rates of nicotine inactivation by CYP2A5. Psychopharmacology (Berl) (2006) 1.14
Human genes involved in copy number variation: mechanisms of origin, functional effects and implications for disease. Cytogenet Genome Res (2009) 1.13
Identification of novel CYP2A6*1B variants: the CYP2A6*1B allele is associated with faster in vivo nicotine metabolism. Clin Pharmacol Ther (2007) 1.06
Gene amplification and microsatellite polymorphism underlie a recent insect host shift. Proc Natl Acad Sci U S A (2013) 1.05
New CYP2A6 gene deletion and conversion variants in a population of Black African descent. Pharmacogenomics (2010) 1.05
Strain-dependent effects of acute, chronic, and withdrawal from chronic nicotine on fear conditioning. Behav Genet (2011) 1.03
Developmental effects of acute, chronic, and withdrawal from chronic nicotine on fear conditioning. Neurobiol Learn Mem (2012) 1.01
CYP2A6 and CYP2B6 genetic variation and its association with nicotine metabolism in South Western Alaska Native people. Pharmacogenet Genomics (2012) 1.00
Design, baseline characteristics, and retention of African American light smokers into a randomized trial involving biological data. Trials (2011) 0.96
Copy number variants in pharmacogenetic genes. Trends Mol Med (2011) 0.96
Association of CYP2A6 deletion polymorphism with smoking habit and development of pulmonary emphysema. Thorax (2003) 0.95
'Smoking genes': a genetic association study. PLoS One (2011) 0.94
Associations of CYP2A6 genotype with smoking behaviors in southern China. Addiction (2011) 0.93
Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism. Br J Clin Pharmacol (2002) 0.93
PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6. Pharmacogenet Genomics (2012) 0.92
Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes. Hum Genet (2012) 0.92
Positive and negative effects of alcohol and nicotine and their interactions: a mechanistic review. Neurotox Res (2011) 0.88
The genetics of nicotine dependence: relationship to pancreatic cancer. World J Gastroenterol (2006) 0.88
Characterization of the novel CYP2A6*21 allele using in vivo nicotine kinetics. Eur J Clin Pharmacol (2006) 0.87
A link between adolescent nicotine metabolism and smoking topography. Cancer Epidemiol Biomarkers Prev (2009) 0.86
In vivo evaluation of CYP2A6 and xanthine oxidase enzyme activities in the Serbian population. Eur J Clin Pharmacol (2010) 0.86
CYP2A6 genotyping methods and strategies using real-time and end point PCR platforms. Pharmacogenomics (2015) 0.81
High CYP2A6 enzyme activity as measured by a caffeine test and unique distribution of CYP2A6 variant alleles in Ethiopian population. OMICS (2013) 0.81
Concordance rates for smoking among African-American twins. J Natl Med Assoc (2007) 0.81
Integrating genetic studies of nicotine addiction into public health practice: stakeholder views on challenges, barriers and opportunities. Public Health Genomics (2011) 0.80
Cytochrome p450 metabolism of betel quid-derived compounds: implications for the development of prevention strategies for oral and pharyngeal cancers. ScientificWorldJournal (2013) 0.79
Precision Medicine for Tobacco Dependence: Development and Validation of the Nicotine Metabolite Ratio. J Neuroimmune Pharmacol (2016) 0.79
Simultaneous measurement of urinary total nicotine and cotinine as biomarkers of active and passive smoking among Japanese individuals. Environ Health Prev Med (2012) 0.79
Applications of CYP-450 expression for biomonitoring in environmental health. Environ Health Prev Med (2008) 0.79
Parasite-host interaction in malaria: genetic clues and copy number variation. Genome Med (2009) 0.78
Carbamazepine but not valproate induces CYP2A6 activity in smokers with mental illness. Cancer Epidemiol Biomarkers Prev (2010) 0.77
Phenobarbital increases monkey in vivo nicotine disposition and induces liver and brain CYP2B6 protein. Br J Pharmacol (2006) 0.77
Nicotine intake and smoking topography in smokers with bipolar disorder. Bipolar Disord (2012) 0.76
Inactivation of CYP2A6 by the Dietary Phenylpropanoid trans-Cinnamic Aldehyde (Cinnamaldehyde) and Estimation of Interactions with Nicotine and Letrozole. Drug Metab Dispos (2016) 0.75
Distribution of polymorphic variants of CYP2A6 and their involvement in nicotine addiction. EXCLI J (2017) 0.75
Genetics of tobacco use. Tob Induc Dis (2004) 0.75
EFFECT OF CYP2A6*4 GENETIC POLYMORPHISMS ON SMOKING BEHAVIORS AND NICOTINE DEPENDENCE IN A GENERAL POPULATION OF JAPANESE MEN. Fukushima J Med Sci (2015) 0.75
A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther (1981) 69.83
Generation of influenza A viruses entirely from cloned cDNAs. Proc Natl Acad Sci U S A (1999) 14.90
Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict (1989) 6.58
Drug therapy: drug disposition in old age. N Engl J Med (1982) 3.04
Promoter elements in the influenza vRNA terminal structure. RNA (1996) 2.97
Nosocomial bronchopneumonia in the critically ill. Histologic and bacteriologic aspects. Am Rev Respir Dis (1992) 2.55
Ultrastructure of the gastric mucosa harboring Campylobacter-like organisms. Am J Clin Pathol (1986) 2.52
Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion. Clin Pharmacol Ther (2008) 2.49
A comparison of electrophysiologically guided antiarrhythmic drug therapy with beta-blocker therapy in patients with symptomatic, sustained ventricular tachyarrhythmias. N Engl J Med (1992) 2.40
Clinical pharmacology and therapeutics of benzodiazepines. Can Med Assoc J (1978) 2.40
Induction of interleukin-8 synthesis integrates effects on transcription and mRNA degradation from at least three different cytokine- or stress-activated signal transduction pathways. Mol Cell Biol (1999) 2.39
Germline integration of moloney murine leukemia virus at the Mov13 locus leads to recessive lethal mutation and early embryonic death. Cell (1983) 2.33
Molecular changes in the polymerase genes (PA and PB1) associated with high pathogenicity of H5N1 influenza virus in mallard ducks. J Virol (2007) 2.20
Risk factors and clinical relevance of nosocomial maxillary sinusitis in the critically ill. Am J Respir Crit Care Med (1994) 2.19
The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther (2007) 2.18
Nicotine metabolism defect reduces smoking. Nature (1998) 2.17
Can severity-of-illness indices for neonatal intensive care predict outcome at 4 years of age? Acta Paediatr (2002) 2.16
Catheter ablation of atrial flutter due to amiodarone therapy for paroxysmal atrial fibrillation. Eur Heart J (2000) 2.07
A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J Pharmacol Exp Ther (1997) 2.06
Treatment of acetaminophen poisoning. Can Med Assoc J (1981) 2.05
Human bone morphogenetic protein 2 contains a heparin-binding site which modifies its biological activity. Eur J Biochem (1996) 1.98
Attenuation of the euphoric effects of cocaine by the dopamine D1/D5 antagonist ecopipam (SCH 39166) Arch Gen Psychiatry (1999) 1.94
Tobacco smoke exposure and pregnancy outcome among working women. A prospective study at prenatal care centers in Orebro County, Sweden. Am J Epidemiol (1991) 1.92
Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. Mol Psychiatry (2006) 1.89
Duodenal intraepithelial lymphocyte-count revisited. Scand J Gastroenterol (2004) 1.88
Binding of drugs to serum albumin (first of two parts). N Engl J Med (1976) 1.85
Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers. Clin Pharmacol Ther (2009) 1.83
Programmes to reduce pelvic inflammatory disease--the Swedish experience. Lancet (1998) 1.81
Decreasing incidences of gonorrhea- and chlamydia-associated acute pelvic inflammatory disease. A 25-year study from an urban area of central Sweden. Sex Transm Dis (1997) 1.79
Changes in renal function after clinical islet transplantation: four-year observational study. Am J Transplant (2007) 1.78
Inter- and intrasubject variation in diazepam free fraction. Clin Pharmacol Ther (1979) 1.76
Alcohol intoxication and withdrawal. N Engl J Med (1976) 1.74
Neuropsychological test results and symptoms among workers with well-defined long-term exposure to lead. Br J Ind Med (1983) 1.73
Kinetics and clinical importance of displacement of warfarin from albumin by acidic drugs. Ann N Y Acad Sci (1971) 1.67
The ambiguity of adverse drug reactions. Eur J Clin Pharmacol (1977) 1.64
Histologic aspects of pulmonary barotrauma in critically ill patients with acute respiratory failure. Intensive Care Med (1993) 1.63
Genetic variation in nicotine metabolism predicts the efficacy of extended-duration transdermal nicotine therapy. Clin Pharmacol Ther (2010) 1.59
Potentiation of warfarin-induced hypoprothrombinemia by chloral hydrate. N Engl J Med (1970) 1.59
Displacement of warfarin from human albumin by diazoxide and ethacrynic, mefenamic, and nalidixic acids. Clin Pharmacol Ther (1970) 1.58
Systematic review: secondary prevention with band ligation, pharmacotherapy or combination therapy after bleeding from oesophageal varices. Aliment Pharmacol Ther (2009) 1.56
Development of optimal treatment tactics for alcohol withdrawal. I. Assessment and effectiveness of supportive care. J Clin Psychopharmacol (1981) 1.56
Mutation in bone morphogenetic protein receptor-IB is associated with increased ovulation rate in Booroola Mérino ewes. Proc Natl Acad Sci U S A (2001) 1.51
Relation between concentrations of metronidazole and Bacteroides spp in faeces of patients with Crohn's disease and healthy individuals. J Clin Pathol (1981) 1.49
Conventional and dedicated atrial overdrive pacing for the prevention of paroxysmal atrial fibrillation: the AFTherapy study. Europace (2007) 1.49
Drug therapy. Binding of drugs to serum albumin (second of two parts). N Engl J Med (1976) 1.49
Genetically decreased CYP2A6 and the risk of tobacco dependence: a prospective study of novice smokers. Tob Control (2004) 1.47
Efficacy of automatic multimodal device therapy for ventricular tachyarrhythmias as delivered by a new implantable pacing cardioverter-defibrillator. Results of a European multicenter study of 102 implants. Circulation (1992) 1.45
Canadian Native Indians exhibit unique CYP2A6 and CYP2C19 mutant allele frequencies. Clin Pharmacol Ther (1998) 1.44
Three mixed venous saturation catheters in patients with circulatory shock and respiratory failure. Chest (1990) 1.42
Gene transfer of heterologous G protein-coupled receptors to cardiomyocytes: differential effects on contractility. Circ Res (2001) 1.42
Prevention of gram negative nosocomial bronchopneumonia by intratracheal colistin in critically ill patients. Histologic and bacteriologic study. Intensive Care Med (1994) 1.42
Fast pathway ablation in patients with common atrioventricular nodal reentrant tachycardia and prolonged PR interval during sinus rhythm. Eur Heart J (1998) 1.40
Shift work, nitrous oxide exposure, and spontaneous abortion among Swedish midwives. Occup Environ Med (1996) 1.40
In vitro quantitation of benzodiazepine lipophilicity: relation to in vivo distribution. Br J Anaesth (1983) 1.39
[Toy cap pistols and their effect on hearing]. HNO (1998) 1.39
Amitriptyline and ethanol: pharmacokinetic and pharmacodynamic interaction. Eur J Clin Pharmacol (1983) 1.38
An application of computers to curriculum review and planning. J Med Educ (1986) 1.38
Land-based birds as potential disseminators of avian mammalian reassortant influenza A viruses. Avian Dis (2003) 1.35
Overview of the pharmacogenomics of cigarette smoking. Pharmacogenomics J (2007) 1.35
Determination of the strange-quark density of the proton from ATLAS measurements of the W→ℓν and Z→ℓℓ cross sections. Phys Rev Lett (2012) 1.34
Diazepam actions and plasma concentrations following ethanol ingestion. Eur J Clin Pharmacol (1977) 1.33
Measurement issues in postpartum depression part 1: anxiety as a feature of postpartum depression. Arch Womens Ment Health (2003) 1.30
Heavy lifting during pregnancy--a hazard to the fetus? A prospective study. Int J Epidemiol (1990) 1.29
Comparative efficacy of propranolol and chlordiazepoxide in alcohol withdrawal. J Stud Alcohol (1977) 1.28
Variations in drug free fraction during alcohol withdrawal. Br J Clin Pharmacol (1983) 1.28
Observation of associated near-side and away-side long-range correlations in sqrt[s(NN)]=5.02 TeV proton-lead collisions with the ATLAS detector. Phys Rev Lett (2013) 1.27
Withdrawal reaction after long-term therapeutic use of benzodiazepines. N Engl J Med (1986) 1.27
Impact of intraocular pressure regulation on visual fields in open-angle glaucoma. Ophthalmology (1999) 1.26
Diazepam loading: simplified treatment of alcohol withdrawal. Clin Pharmacol Ther (1983) 1.26
Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk. Drug Metab Dispos (2001) 1.25
A systematic review of the peripheral analgesic effects of intraarticular morphine. Anesth Analg (2001) 1.24
Drug kinetics and alcohol ingestion. Clin Pharmacokinet (1979) 1.22
Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking. Clin Pharmacol Ther (2000) 1.22
Cost effectiveness of two rehabilitation programmes for neck and back pain patients: A seven year follow-up. Pain (2009) 1.21
Risk factors for tobacco dependence in adolescent smokers. Tob Control (2006) 1.20
Search for dark matter candidates and large extra dimensions in events with a photon and missing transverse momentum in pp collision data at sqrt[s]=7 TeV with the ATLAS detector. Phys Rev Lett (2013) 1.19
A cluster of three GABAA receptor subunit genes is deleted in a neurological mutant of the mouse p locus. Nature (1993) 1.19
Assessment of nicotine dependence symptoms in adolescents: a comparison of five indicators. Tob Control (2002) 1.19
Drug therapy: Drugs to decrease alcohol consumption. N Engl J Med (1981) 1.18
Evaluation of blood bank practices in Karachi, Pakistan, and the government's response. Health Policy Plan (2000) 1.18
Long-term codeine use is associated with depressive symptoms. J Clin Psychopharmacol (1999) 1.18
Decreased lung function in long-term asbestos cement workers: a cross-sectional study. Am J Ind Med (1984) 1.17
A single stem-loop structure within the HTLV-1 Rex response element is sufficient to mediate Rex activity in vivo. Virology (1994) 1.17
CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. Clin Pharmacol Ther (1993) 1.16
Biomarkers for smoking cessation. Clin Pharmacol Ther (2013) 1.15
Pharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafiltration. Antimicrob Agents Chemother (1998) 1.15
Winter weather conditions and myocardial infarctions. Scand J Soc Med (1991) 1.14
In vitro correlates of benzodiazepine cerebrospinal fluid uptake, pharmacodynamic action and peripheral distribution. J Pharmacol Exp Ther (1983) 1.14
Search for a supersymmetric partner to the top quark in final states with jets and missing transverse momentum at sqrt[s] = 7 TeV with the ATLAS detector. Phys Rev Lett (2012) 1.13
A case-control study of motor neurone disease: its relation to heritability, and occupational exposures, particularly to solvents. Br J Ind Med (1992) 1.13
Methadone binding to orosomucoid (alpha 1-acid glycoprotein): determinant of free fraction in plasma. Clin Pharmacol Ther (1981) 1.13
One-incision approach for insertion of implantable cardioverter defibrillators. Ann Thorac Surg (1994) 1.12
Treatment, long-term outcome and prognostic variables in 214 unselected AML patients in Sweden. Br J Cancer (2000) 1.11
Shift work, nitrous oxide exposure and subfertility among Swedish midwives. Int J Epidemiol (1996) 1.10
Adjustment of incidence rates after an estimate of completeness and accuracy in registration of acute leukemias in a Swedish population. Leuk Lymphoma (2001) 1.10
Influence of age and previous use of diazepam dosage required for endoscopy. Can Med Assoc J (1978) 1.09